KATP Channel Openers: Structure-Activity Relationships and Therapeutic Potential

Medicinal Research Reviews

Volumn 24, Issue 2, 2004, Pages 213-266

  Mannhold, Raimund ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Asthma; Benzopyrans; Cyanoguanidines; Diazoxide; Diversity; KATP channel openers (KCOs); KATP channels; Myocardial ischemia; Nicorandil; Regulation; Structure activity relationships; Therapeutic potential; Thioformamides; Topology

Indexed keywords

2 (6 CYANO 2,2 DIMETHYL 2H 1 BENZOPYRAN 4 YL)PYRIDINE 1 OXIDE; 2 CYANO 1 (1,1 DIMETHYLPROPYL) 3 (3 PYRIDYL)GUANIDINE; 3 (2,4 DICHLORO 6 METHYLBENZYLAMINO) 4 (1,1 DIMETHYLPROPYLAMINO) 3 CYCLOBUTENE 1,2 DIONE; 3,4 DIHYDRO 3 HYDROXY 2,2 DIMETHYL 4 (3 OXO 1 CYCLOPENTEN 1 YLOXY) 2H 1 BENZOPYRAN 6 CARBONITRILE; 4 (N ACETYL N BENZYLOXYAMINO) 3 HYDROXY 2,2 DIMETHYL 6 CHROMANCARBONITRILE; 4 [(1,6 DIHYDRO 1 METHYL 6 OXO 3 PYRIDAZINYL)AMINO] 3 HYDROXY 2,2 BIS(METHOXYMETHYL)CHROMAN 6 CARBONITRILE; 7,8 DIHYDRO 7 HYDROXY 6,6 DIMETHYL 8 (2 OXO 1 PIPERIDYL) 6H PYRANO[2,3 F][2,1,3]BENZOXADIAZOLE; 9 (3 CYANOPHENYL) 3,4,6,7,9,10 HEXAHYDRO 1,8(2H,5H) ACRIDINEDIONE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; APRIKALIM; BAY X9228; BENZOPYRAN DERIVATIVE; BIMAKALIM; BRL 49381; CELIKALIM; CROMAKALIM; CYCLOBUTENEDIONE DERIVATIVE; DIAZOXIDE; DICYANODIAMIDE DERIVATIVE; DIHYDROPYRIDINE DERIVATIVE; GLIBENCLAMIDE; INSULIN; KC 515; LEMAKALIM; METHANOL DERIVATIVE; MINOXIDIL SULFATE; N (2 CYANOETHYL) 2,2 BIS(FLUOROMETHYL) 6 NITRO 2H 1 BENZOPYRAN 4 CARBOTHIOAMIDE; N (4 BENZOYLPHENYL) 3,3,3 TRIFLUORO 2 HYDROXY 2 METHYLPROPIONAMIDE; NICORANDIL; PINACIDIL; PKF 217744; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; PYRIDYL NITRATE DERIVATIVE; RILMAKALIM; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR; THIADIAZINE DERIVATIVE; THIOFORMAMIDE DERIVATIVE; U 96501; UNCLASSIFIED DRUG; UNINDEXED DRUG; ABC TRANSPORTER; ANTIDIABETIC AGENT; DRUG RECEPTOR; INWARDLY RECTIFYING POTASSIUM CHANNEL;

ANTIHYPERTENSIVE ACTIVITY; ASTHMA; HEART MUSCLE ISCHEMIA; HEART MUSCLE POTENTIAL; HUMAN; HYPERTENSION; INSULIN RELEASE; NEUROTRANSMITTER RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SMOOTH MUSCLE RELAXATION; STRUCTURE ACTIVITY RELATION; URINE INCONTINENCE; ANIMAL; BINDING SITE; CHANNEL GATING; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; RESEARCH; SENSITIVITY AND SPECIFICITY;

ADENOSINE TRIPHOSPHATE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BINDING SITES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; ION CHANNEL GATING; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG; RESEARCH; SENSITIVITY AND SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1242337465     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10060     Document Type: Review

References (359)

1. Nelson DJ, Chan HC. Ion channel structure and modulation. In: Testa B, Kyburz E, Fuhrer W, Giger R, editors. Perspectives in medicinal chemistry. Basel, Weinheim: VHCA, VCH publishers; 1993. pp 349-371.
2. Shieh C-C, Coghlan MJ, Sullivan JP, Gopalakrishnan M. Potassium channels: Molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 2000;52:557-593.
3. Ford JW, Stevens EB, Treherne JM, Packer J, Bushfield M. Potassium channels: Gene family, therapeutic relevance, high-throughput screening technologies and drug discovery. Progr Drug Res 2002;58:133-168.
4. Coghlan MJ, Carroll WA, Gopalakrishnan M. Recent developments in the biology and medicinal chemistry of potassium channel modulators: Update from a decade of progress. J Med Chem 2001;44:1627-1653.
5. Isomoto S, Kondo C, Kurachi Y. Inwardly rectifying potassium channels: Their molecular heterogeneity and function. Jpn J Physiol 1997;47:11-39.
6. ATP channels. J Biol Chem 2000;275:1137-1144.
7. Ashcroft SJ, Ashcroft FM. Properties and functions of ATP-sensitive K-channels. Cell Signal 1990;2:197-214.
8. Quayle JM, Nelson MT, Standen NB. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 1997;77:1165-1232.
9. + channels in pancreatic, cardiac, and vascular smooth muscle cells. Am J Physiol 1998;43:C25-C37.
10. + channels. Trends Neurosci 1998;21:288-294.
11. Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocrine Rev 1999;20:101-135.
12. Seino S. ATP-sensitive potassium channels: A model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol 1999;61:337-362.
13. + channel openers. Pharmacol Ther 2000;85:39-53.
14. Grover GJ, Garlid KD. ATP-sensitive potassium channels: A review of their cardioprotective pharmacology. J Mol Cell Cardiol 2000;32:677-695.
15. +-channels in cardiac muscle. Nature 1983;305:147-148.
16. +-channels in pancreatic β-cells. Nature 1984;311:271-273.
17. Spruce AE, Standen NB, Stanfield PR. Voltage-dependent ATP-sensitive potassium channels of skeletal muscle membrane. Nature 1985;316:736-738.
18. + channel. Proc Natl Acad Sci USA 1988;85:9816-9820.
19. Ashford MLJ, Sturgess NC, Trout NJ, Gardner NJ, Hales CN. Adenosine-5′-triphosphate-sensitive ion channels in neonatal rat cultured central neurones. Pflügers Arch 1988;412:297-304.
20. +-channels in atrial smooth muscle. Science 1989;245:177-180.
21. ATP channel. Nature 1994;370:456-459.
22. + channels sensitive to antidiabetic sulfonylureas are present in adenohypophysis and are involved in growth hormone release. Proc Natl Acad Sci USA 1993;90:1340-1344.
23. +-channel by protein kinase A and C. Proc Natl Acad Sci USA 1991;88:9722-9725.
24. +-channels. Science 1990;247:852-854.
25. ATP channels in vascular smooth muscle. Cardiovasc Res 1994;28:797-804.
26. ATP channel complex. J Gen Physiol 1997;110:655-664.
27. ATP channels. Physiol Rev 1998;78:227-245.
28. Miki T, Inagaki N, Nagashima K, Gonoi T, Seino S. Structure and function of ATP-sensitive potassium channels. Curr Top Membr 1999;46:373-385.
29. ATP channels. Annu Rev Physiol 1999;60:667-687.
30. Inagaki N, Tsuura Y, Namba N, Masuda K, Gonoi T, Horie M, Seino Y, Mizuta M, Seino S. Cloning and functional characterization of a novel ATP-sensitive potassium channel ubiquitously expressed in rat tissues, including pancreatic islets, pituitary, skeletal muscle, and heart. J Biol Chem 1995;270:5691-5694.
31. ATP: An inward rectifier subunit plus the sulfonylurea receptor. Science 1995;270:1166-1169.
32. Higgins CF. The ABC of channel regulation. Cell 1995;82:693-696.
33. Demolombe S, Escande D. ATP-binding cassette proteins as targets for drug discovery. Trends Pharmacol Sci 1996;17:273-275.
34. Jones PM, George AM. Subunit interactions in ABC transporters: Towards a functional architecture. FEMS Microbiol Lett 1999;179:187-202.
35. Tusnády GE, Bakos E, Váradi A, Sarkadi B. Membrane topology distinguishes a subfamily of the ATP-binding cassette (ABC) transporters. FEBS Lett 1997;402:1-3.
36. Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement JP IV, Boyd AE III, Gonzalez G, Herrera-Sosa H, Nguy K, Bryan J, Nelson DA. Cloning of the β cell high-affinity sulfonylurea receptor: A regulator of insulin secretion. Science 1995;268:423-426.
37. Thomas PM, Cote GJ, Wohlk N, Haddad B, Mathew PM, Rabl W, Aguilar-Bryan L, Gagel RF, Bryan J. Mutations in the sulfonylurea receptor gene in familial hyperinsulinemic hypoglycemia of infancy. Science 1995;268:426-429.
38. ATP channels in pancreatic β-cells causes persistent hyperinsulinemic hypoglycemia of infancy. Nature Med 1996;2:1344-1347.
39. + channels. Neuron 1996;16:1011-1017.
40. + channel. J Biol Chem 1996;271:24321-24324.
41. ATP channels. Diabetes 1996;45:1439-1445.
42. Sakura H, Ämmälä C, Smith PA, Gribble FM, Ashcroft FM. Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed in pancreatic β-cells, brain, heart, and skeletal muscle. FEBS Lett 1995;377:338-344.
43. ATP channels in dopaminergic midbrain neurones. EMBO J 1999;18:833-846.
44. ATP channel-forming Kir6.2 subunit and the sulfonylurea receptor SUR1 in rodent brain. FEBS Lett 1997;401:59-64.
45. ATP channels. Functional identity with the native channels from the sarcolemma of human ventricular cells. Circ Res 1998;83:1132-1143.
46. + channel expressed in a mammalian cell line, HEK2293T cells. Pflügers Arch 1998;435:595-603.
47. + channel. J Physiol 1997;499:715-720.
48. Beech DJ, Zhang H-L, Nakao K, Bolton TB. K channel activation by nucleotide diphosphates and its inhibition by glibenclamide in vascular smooth muscle cells. Br J Pharmacol 1993;110:573-582.
49. Zhang H-L, Bolton TB. Two types of ATP-sensitive potassium channels in rat portal vein smooth muscle cells. Br J Pharmacol 1996;118:105-114.
50. Ashcroft FM. Adenosine 5′-triphosphate-sensitive potassium channels. Annu Rev Neurosci 1988;11:97-118.
51. 2+ ions. J Physiol (Lond) 1989;416:349-367.
52. + channels in guinea pig cardiac myocytes. Amer J Physiol 1990;258:H45-H50.
53. + channel in ventricular cell of guinea-pig. J Physiol (Lond) 1991;437:239-256.
54. + channels toward intracellular nucleoside diphosphates. Neuron 1994;12:1-20.
55. Terzic A, Tung RT, Kurachi Y. Nucleotide regulation of ATP-sensitive potassium channels. Cardiovasc Res 1994;28:746-753.
56. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995;268:C799-C822.
57. + channel openers. Am J Physiol 1995; C525-C545.
58. + channels. News Physiol Sci 1998;13:131-137.
59. 2+-independent ATP binding of the sulfonylurea receptor SUR1. J Biol Chem 1997;272:22983-22986.
60. +-channel by 8-azido-ATP. J Biol Chem 1999;274:3931-3933.
61. + channels in the absence of the sulfonylurea receptor. Nature 1997;387:179-183.
62. Gribble FM, Tucker SJ, Ashcroft FM. The essential role of the Walker A motifs of SUR1 in K-ATP channel activation by Mg-ADP and diazoxide. EMBO J 1997;16:1145-1152.
63. + channel to the actin cytoskeleton. Pflügers Arch 1996;431:504-512.
64. 2. Science 1996;273:956-959.
65. ATP channels. Science 1998;282:1138-1141.
66. Walker JE, Saraste MJ, Runswick MJ, Gay NJ. Distantly related sequences in the alpha and beta subunits of ATP synthetase, myosin, kinases, and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1982;1:945-951.
67. + channels for potassium-channel-openers. FEBS Lett 1993;325:276-280.
68. Kim D, Clapham DE. Potassium channels in cardiac cells activated by arachidonic acid and phospholipids. Science 1989;244:1174-1176.
69. 1 receptors by G proteins in rat ventricular myocytes. Am J Physiol 1990;259:H820-H826.
70. ATP channels in guinea pig ventricular cells. Am J Physiol 1995;269:H1625-H1633.
71. ATP channels and nitric oxide in conscious dogs. Circulation 1997;95:1568-1576.
72. Ben-Ari Y, Lazdunski M. Galanin protects hippocampal neurons from the functional effects of anoxia. Eur J Pharmacol 1989;165:331-332.
73. 1-selectice adenosine agonist in porcine coronary artery-involvement of potassium channels. J Pharmacol Exp Ther 1992;260:437-443.
74. + channels. Nature 1990;344:770-773.
75. O'Rourke B. Pathophysiological and protective roles of mitochondrial ion channels. J Physiol 2000;529.1:23-36.
76. + channel openers? Trends Pharmacol Sci 1999;20:157-161.
77. Kicinska A, Debska G, Kunz W, Szewczyk A. Mitochondrial potassium and chloride channels. Acta Biochim Pol 2000;47:541-551.
78. Szewczyk A, Wojtczak L. Mitochondria as a pharmacological target. Pharmacol Rev 2002;54:101-127.
79. Seharaseyon J, Ohler A, Sasaki N, Fraser H, Sato T, Johns DC, O'Rourke B, Marbán E. Molecular composition of mitochondrial ATP-sensitive potassium channels probed by viral gene transfer. J Mol Cell Cardiol 2000;32:1923-1930.
80. + channel in the mitochondrial inner membrane. Nature 1991;352:244-247.
81. + channel from rat liver and beef heart mitochondria. J Biol Chem 1992;267:26062-26069.
82. ATP channel by long-chain acyl-CoA esters and activation by guanine nucleotides. J Biol Chem 1996;271:32084-32088.
83. ATP channels. Mol Pharmacol 1999;55:1000-1005.
84. ATP channels. Mol Pharmacol 2001;59:225-230.
85. + channels? Trends Pharmacol Sci 1993;14:332-337.
86. Quast U. Effects of potassium channel activators in isolated blood vessels. In: Evans JM, Hamilton TC, Longman SD, Stemp G, editors. Potassium channels and their modulators. London: Taylor & Francis; 1996. pp 173-195.
87. Clapham JC. In vivo vascular effects of potassium channel activators. In: Evans JM, Hamilton TC, Longman SD, Stemp G, editors. Potassium channels and their modulators. London: Taylor & Francis; 1996. pp 197-220.
88. ATP channel opemers. Trends Pharmacol Sci 2000;21:439-445.
89. ATP channels. Biochem Soc Trans 2002;30:333-335.
90. ATP-channels and basal vascular tone. Cardiovasc Res 1994;28:811-817.
91. + current in canine coronary smooth muscle cells. Pflügers Arch 1994;427:110-120.
92. Bray KM, Weston AH, Duty S, Newgreen DT, Longmore J, Edwards G, Brown TJ. Differences between the effects of cromakalim and nifedipine on agonist-induced responses in rabbit aorta. Br J Pharmacol 1991;102:337-344.
93. Jaspert S. 2001. Wirkung und Selektivität von Kaliumkanalö ffnern bei der Relaxation der glatten Muskulatur verschiedener Gefäßgebiete im Vergleich zur Atemwegsmuskulatur. MD Thesis, Heinrich-Heine-Universität Düsseldorf
94. Lawson K, Barras M, Zazzi-Sudriez E, Martin DJ, Armstrong JM, Hicks PE. Differential effects of endothelin-I on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers. Br J Pharmacol 1992;107:58-65.
95. Randall MD, Griffith TM. Modulation of vasodilation to levcromakalim by hypoxia and EDRF in the isolated perfused rabbit ear: A comparison with pinacidil, sodium nitroprusside and verapamil. Br J Pharmacol 1993;109:386-393.
96. Gopalakrishnan M, Janis RA, Triggle DJ. ATP-sensitive K channels: Pharmacologic properties and therapeutic potential. Drug Dev Res 1993;28:95-127.
97. Edwards G, Weston AH. The pharmacology of ATP-sensitive potassium channels. Annu Rev Pharmacol Toxicol 1993;33:597-637.
98. Lawson K, Hicks PE. Potassium channel openers: Pharmacological anomalies suggest heterogeneous sites of action. Curr Opin Invest Drugs 1993;2:1209-1216.
99. - channel inhibitor in vascular smooth muscle cells. J Membr Biol 1994;137:59-70.
100. Paciorek PM, Burden DT, Burke YM, Cowlrick IS, Perkins RS, Taylor JC, Waterfall JF. Preclinical pharmacology of RO 31-6930, a new potassium channel opener J Cardiovasc Pharmacol 1990;15:188-197.
101. Morin ME, Wojdan A, Oshiro G, Colatsky T, Quagliato DA. Antihypertensive and hypotensive effects of the potassium channel activator, WAY-120,491 in spontaneously hypertensive (SHR), DOCA-salt (DOCA), 2K-1C Goldblatt hypertensive (2K-1C) and Wistar Kyoto normotensive rats (WKY). FASEB J 1990;4:A746.
102. Soll RM, Quagliato DA, Deininger DD, Dollings PJ, Joslyn BL, Dolak TM, Lee SJ, Bohan C, Wojdan A, Morin ME, Oshiro G. Antihypertensive benzopyran-related potassium channel activators: A role for lipophilicity. Bioorg Med Chem Lett 1991;1:591-594.
103. + channel opener with less tachycardia: Antihypertensive effects in hypertensive rats and dogs in conscious state. J Pharmacol Exp Ther 1992;261:730-736.
104. Horino H, Mimura T, Kobayashi S, Ohta M, Kubo H, Ito K, Tsumura M, Kitagawa M. Novel potassium channel opener prodrugs with a slow onset and prolonged duration of action. Chem Pharm Bull 2000;48:490-495.
105. Manley PW, Quast U, Andres H, Bray KM. Synthesis of and radioligand binding studies with a tritiated pinacidil analogue: Receptor interactions of structurally different classes of potassium channel openers and blockers. J Med Chem 1993;36:2004-2010.
106. 3H]P1075 in rat isolated aorta: Relationship to functional effects of openers and blockers. Mol Pharmacol 1993;43:474-481.
107. Hoffman FJ, Jr., Lenfers JB, Niemers E, Pleiss U, Scriabine A, Janis RA. High affinity binding of a potassium channel agonist to intact rat insulinoma cells. Biochem Biophys Res Commun 1993;190:551-558.
108. 3H]cromakalim in vascular and bronchial smooth muscle cells. Br J Pharmacol 1992;107:396P.
109. ATP channel opener with a benzopyran structure. Br J Pharmacol 2001;133:275-285.
110. + channel openers in rat aorta. J Biol Chem 1992;267:11689-11692.
111. 3H]P1075. FASEB J 1993;7:A354.
112. Dickinson KEJ, Bryson CC, Cohen RB, Rogers L, Green DW, Atwal KS. Nucleotide regulation and characteristics of potassium channel opener binding to skeletal muscle membranes. Mol Pharmacol 1997;52:473-481.
113. ATP) openers to cardiac membranes: Correlation of binding affinities with cardioprotective and smooth muscle relaxing properties. J Med Chem 1998;41:271-275.
114. Lemoine H, Mannhold R, Grittner D. Binding studies with potassium channel openers (KCO) in smooth muscle cells of calf coronary artery as compared to rat cardiomyocytes. Naunyn-Schmiedeberg's Arch. Pharmacol 1996;353(Suppl):R54.
115. Lemoine H, Teschemacher A, Mannhold R, Divanac'h A. Binding studies with potassium channel openers in intact smooth muscle cells of calf trachea. Naunyn-Schmiedeberg's Arch. Pharmacol 1997;355(Suppl):R74.
116. Schwanstecher M, Sieverding C, Dörschner H, Gross I, Aguilar-Bryan L, Schwanstecher C, Bryan J. Potassium channel openers require ATP to bind to and act through sulfonylurea receptors. EMBO J 1998;17:5529-5535.
117. + channel modulator binding to sulfonylurea receptors SUR2A and SUR2B: Opposite effects of MgADP. Mol Pharmacol 1999;55:832-840.
118. ATP channel modulator binding to the recombinant sulfonylurea receptor SUR2B. Br J Pharmacol 1998;125:577-583.
119. ATP) channels which suppresses airways hyperreactivity at doses devoid of cardiovascular effects. Naunyn-Schmiedeberg's Arch Pharmacol 2002;365:220-230.
120. ATP channel openers in the vascular smooth muscle cell line, A 10. Br J Pharmacol 1997;122:1119-1126.
121. Mannhold R, Lemoine H, Jaspert S. Comparison of binding and relaxant properties of potassium channel openers (KCO) in calf coronary arteries. Naunyn-Schmiedeberg's Arch Pharmacol 1996;353(Suppl):R54.
122. ATP channel complex. FASEB J 2000;14:1943-1952.
123. ATP channels containing SUR2A or SUR2B subunits to nucleotides and pinacidil. Mol Parmacol 2000;58:1318-1325.
124. ATP channel Kir6.2/SUR2A. Mol Parmacol 2000;57:1256-1261.
125. Reimann F, Ashcroft FM, Gribble FM. Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes 2001;50:2253-2259.
126. Uhde I, Toman A, Gross I, Schwanstecher C, Schwanstecher M. Identification of the potassium channel opener site on sulfonylurea receptors. J Biol Chem 1999;274:28079-28082.
127. + channels linked to the green fluorescent protein in human embryonic kidney cells (HEK293). J Physiol 1998;510:333-345.
128. Mikhailov MV, Proks P, Ashcroft FM, Ashcroft SJH. Expression of functionally active ATP-sensitive K-channels in insect cells using baculovirus. FEBS Letters 1998;429:390-394.
129. + channels by nicorandil and pinacidil. Br J Pharmacol 1998;124:985-991.
130. + channel openers. J Biol Chem 2000;275:717-720.
131. D'Hahan N, Jacquet H, Moreau C, Catty P, Vivaudou M. A transmembrane domain of the sulfonylurea receptor mediates activation of ATP-sensitive K(+) channels by K(+) channel openers. Mol Pharmacol 1999;56:308-315.
132. D'Hahan N, Moreau C, Prost A-L, Jacquet H, Alekseev AE, Terzic A, Vivaudou M. Pharmacological plasticity of cardiac ATP-sensitive potassium channels toward diazoxide revealed by ADP. Proc Natl Acad Sci USA 1999;96:12162-12167.
133. ATP channel openers. EMBO J 2000;19:6644-6651.
134. ATP channel activity by diazoxide and MgADP. Distinct functions of the two nucleotide binding folds of the sulfonylurea receptor. J Gen Physiol 1997;110:643-654.
135. + channel openers. Trends Pharmacol Sci 1990;11:417-422.
136. Atwal K. Modulation of potassium channels by organic molecules. Med Res Rev 1992;6:569-591.
137. Evans JM, Taylor SG. Potassium channel activators: Pharmacological methods, models, and structure-activity relationships. Prog Med Chem 1994;31:412-446.
138. Empfield JR, Russell K. Potassium channel openers. Ann Rep Med Chem 1995;30:81-90.
139. Edge CM. Conformational analysis of potassium channel activators. In: Evans JM, Hamilton TC, Longman SD, Stemp G, editors. Potassium channels and their modulators. London: Taylor & Francis; 1996. pp 79-97.
140. Ashwood VA, Buckingham RE, Cassidy F, Evans JM, Faruk EA, Hamilton TC, Nash DJ, Stemp G, Willcocks K. Synthesis and antihypertensive activity of 4-(cyclic amido)-2H-1-benzopyrans. J Med Chem 1986;29:2194-2201.
141. Stemp G, Evans JM. Discovery and development of cromakalim and related potassium channel activators. In: Ganellin CR, Roberts SM, editors. Medicinal chemistry. The role of organic chemistry in drug research. London: Academic Press; 1993. pp 141-162.
142. Evans JM, Stemp G. Structure-activity relationships of benzopyran based potassium channel activators. In: Evans JM, Hamilton TC, Longman SD, Stemp G, editors. Potassium channels and their modulators. London: Taylor & Francis; 1996. pp 27-55.
143. Evans JM, Fake CS, Hamilton TC, Poyser RH, Watts EA. Synthesis and antihypertensive activity of substituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols. J Med Chem 1983;26:1582-1589.
144. Buckle DR, Arch JRS, Fenwick AE, Houge-Frydrych CSV, Pinto IL, Smith DG, Taylor SG, Tedder JM. Relaxant activity of 4-amido-3,4-dihydro-2H-1-benzopyran-3-ols and 4-amido-2H-1-benzopyrans on guinea pig isolated trachealis. J Med Chem 1990;33:3028-3034.
145. Bergmann R, Gericke R. Synthesis and antihypertensive activity of 4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyrans and related compounds, new potassium channel activators. J Med Chem 1990;33:492-504.
146. Quagliato DA, Humber LG, Joslyn BL, Soll RM, Browne ENC, Shaw C, van Engen D. The synthesis and structural characterization of WAY-120,491; a novel potassium channel activator. Bioorg Med Chem Lett 1991;1:39-42.
147. Lodge NJ, Colatsky TJ, Cullinan CA, Follmer CH. Electromechanical effects of the putative potassium channel opener celikalim (WAY-120,491) on feline atrial and ventricular muscle. J Pharmacol Exp Ther 1992;261:1153-1159.
148. Gadwood RC, Kamdar BV, Cipkus Dubray LA, Wolfe ML, Smith MP, Watt W, Mizsak SA, Groppi VE. Synthesis and biological activity of spirocyclic benzopyran imidazolone potassium channel openers. J Med Chem 1993;36:1480-1487.
149. Gadwood RC, Thomasco LM, Groppi VE, Burnett BA, Smith MP, Watt W. Chiral spirocyclic benzopyran potassium channel openers: Evidence for the active conformation of levcromakalim. Bioorg Med Chem Lett 1995;5:2101-2104.
150. Attwood MR, Jones PS, Kay PB, Paciorek PM, Redshaw S. The design of a novel class of potassium channel activating drugs, 2-(2,2-dimethylbenzopyran-4-yl)-pyridine-1-oxides. Life Sci 1991;48:803-810.
151. Bergmann R, Eiermann V, Gericke R. 4-Heterocyclyloxy-2H-1-benzopyran potassium channel activators. J Med Chem 1990;33:2759-2767.
152. Gericke R, Harting J, Lues I, Schittenhelm C. 3-Methyl-2H-1-benzopyran potassium channel activators. J Med Chem 1991;34:3074-3085.
153. Quast U, Blarer S, Manley PW, Cook NS, Pally C, Fozard JR. The cardiovascular effects of SDZ PCO 400 in vivo: Comparison with cromakalim. Brit J Pharmacol 1990;99:7P.
154. + channel opener. Brit J Pharmacol 1990;99:6P.
155. Dunne MJ. ATP-dependent potassium channels: Their role and regulation. In: Potassium channels '90-Structure, Modulation and Clinical Exploitation, IBC Conference, London.
156. Burrell G, Evans JM, Hadley MS, Hicks F, Stemp G. Benzopyran potassium channel activators related to cromakalim-heterocyclic amide replacements at position 4. Bioorg Med Chem Letters 1994;4:1285-1290.
157. + channel openers by pharmacophore model. Biorg Med Chem Lett 1993;3:625-631.
158. + channel opener with long duration of action and less tachycardia. Bioorg Med Chem Lett 1993;3:2005-2010.
159. 86Rb efflux in rat aorta. J Cardiovasc Pharmacol 1994;23:220-226.
160. Imagawa J, Yoshida S, Koga T, Kamei K, Nabata H. The effect of a novel benzopyran derivative, KC 399, on the isolated guinea-pig trachealis and human bronchi. Gen Pharmacol 1993;;24:1505-1512.
161. + channel openers. Bioorg Med Chem 2000;8:1393-1405.
162. Ohta M, Koga H, Sato H, Ishizawa T. Comparative molecular field analysis of benzopyran-4-carbothioamide potassium channel openers. Bioorg Med Chem Lett 1994;4:2903-2906.
163. Ishizawa T, Koga H, Ohta M, Sato H, Makino T, Kuromaru K, Taka N, Takahashi T, Sato T, Nabata H. Structure-activity relationships of 6-substituted benzopyran-4-carbothioamide potassium channel openers. Bioorg Med Chem Lett 1993;3:1659-1662.
164. + channel openers. Bioorg Med Chem Letters 1993;3:2627-2630.
165. Bergmann R, Gericke R. The influence of substituents in 3-position on the activity of chroman-type potassium channel activators. Arch Pharm (Weinheim) 1994;327:169-173.
166. Cassidy F, Evans JM, Hadley MS, Haladij AH, Leach PE, Stemp G. Synthesis and antihypertensive activity of 3-[(substituted-carbonyl)amino]-2H-1-benzopyrans. J Med Chem 1992;35:1623-1627.
167. Attwood MR, Brown BS, Dunsdon RM, Hurst DN, Jones PS, Kay PB. Synthesis of homochiral potassium channel openers: Role of the benzopyranyl 3-hydroxyl group in cromkalim and pyridine N-oxides in determining the biological activities of enantiomers. Bioorg Med Chem Lett 1992;2:229-234.
168. ATP channel openers of the benzopyran type. J Mol Graph Modelling 2002;21:37-45.
169. Buckle DR, Eggleston DS, Houge-Frydrych CSV, Pinto IL, Readshaw SA, Smith DG, Webster RAB. Conformational and steric modifications of the pyran ring of the potassium-channel activator cromakalim. J Chem Soc Perkin Trans I 1991;1:2763-2771.
170. Russell K, Brown FJ, Warwick P, Forst J, Grant T, Howe B, Kau ST, Li JH, McLaren FM, Shapiro HS, Trivedi S. A highly potent series of fluoroalkyl benzoxazine pyridine-N-oxide potassium channel openers. Bioorg Med Chem Lett 1993;3:2727-2728.
171. Hirata Y, Aisaka K. Effect of JTV-506, a novel vasodilator, on coronary blood flow in conscious dogs. J Cardiovasc Pharmacol 1997;29:397-405.
172. Cho H, Katoh S, Sayama S, Murakami K, Nakanishi H, Kajimoto Y, Ueno H, Kawasaki H, Aisaka K, Uchida I. Synthesis and selective coronary vasodilatory activity of 3,4-dihydro-2,2-bis(methoxymethyl)-2H-1-benzopyran-3-ol derivatives: Novel potassium channel openers. J Med Chem 1996;39:3797-3805.
173. Burrell G, Cassidy F, Evans JM, Lightowler D, Stemp G. Variation in the aromatic ring of cromakalim: Antihypertensive activity of pyranopyridines and 6-alkyl-2H-1-benzopyrans. J Med Chem 1990;33:3023-3027.
174. Arakawa C, Masuda Y, Yokoyama T, Kawamura N, Tanaka S. The antihypertensive effect of NIP-121, a novel potassium channel opener. Jpn J Pharmacol 1990;52(Suppl 1):311P.
175. +-channel opener in isolated vessels. Naunyn-Schmiedeberg's Arch Pharmacol 1990;342:R17.
176. Mannhold R, Cruciani G, Weber H, Lemoine H, Derix A, Weichel C, Clementi M. 6-Varied benzopyrans as potassium channel activators: Synthesis, vasodilator properties and multivariate analysis. J Med Chem 1999;42:981-991.
177. ATP channel activators. J Med Chem 2002;45:1086-1097.
178. Sanfilippo PJ, McNally JJ, Press JB, Falotico R, Giardino E, Katz LB. Thiophene systems. 15. Synthesis and antihypertensive activity of 7-(subsituted benzamido)-6-hydroxythieno[3,2,-b]pyrans as new potassium channel activitors. Bioorg Med Chem Lett 1993;3:1385-1388.
179. Sanfilippo PJ, McNally JJ, Press JB, Fitzpatrick LJ, Urbanski MJ, Katz LB, Giardino E, Falotico R, Salata J, Moore JB, Jr., Miller W. Thiophene systems. 14. Synthesis and antihypertensive activity of novel 7-(cyclic amido)-6-hydroxythieno[3,2-b]pyrans and related compounds as new potassium channel activators. J Med Chem 1992;35:4425-4433.
180. Smith DG. 4-Amido-3,4-dihydro-2H-1-benzothiopyran-3-ols and their sulphoxide and sulphone derivatives-cromakalim analogs. J Chem Soc Perkin Trans I 1990;3187-3191.
181. Almansa C, Gómez LA, Cavalcanti FL, Rodríguez R, Carceller E, Bartrolí J, García-Rafanell J, Forn J. 2, 2-Dialkylnaphthalen-1-ones as new potassium channel activators. J Med Chem 1993;36:2121-2133.
182. + channels in cardiac myocytes. J Pharmacol Exp Ther 1993;267:1544-1549.
183. Uchida W, Masuda N, Taguchi T, Shibasaki K, Shirai Y, Asano M, Matsumoto Y, Tsuzuki R, Fujikura T, Takenaka T. Pharmacologic profiles of YM934, a novel potassium channel opener. J Cardiovasc Pharmacol 1994;23:180-187.
184. Matsumoto Y, Tsuzuki R, Matsuhisa A, Takayama K, Yoden T, Uchida W, Asano M, Fujita S, Yanagisawa I, Fujikura T. Novel potassium channel activators: Synthesis and structure-activity relationship studies of 3,4-dihydro-2H-1,4-benzoxazine derivatives. Chem Pharm Bull 1996;44:103-114.
185. Matsumoto Y, Tsuzuki R, Matsuhisa A, Masuda N, Yamagiwa Y, Yanagisawa I, Shibanuma T, Nohira H. Novel potassium channel activators. II. Synthesis and pharmacological evaluation of 3,4-dihydro-2H-1, 4-benzoxazine derivatives: Modification of the aromatic part. Chem Pharm Bull 1999;47:971-979.
186. Matsumoto Y, Tsuzuki R, Matsuhisa A, Yoden T, Yamagiwa Y, Yanagisawa I, Shibanuma T, Nohira H. Novel potassium channel openers. Part 4: Transformation of the 1,4-benzoxazine skeleton into 1, 4-benzothiazine, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroquinoxaline, indoline and 1,5-benzoxazepine. Bioorg Med Chem 2000;8:393-404.
187. ATP channel activators. Drugs Fut 2002;27(Suppl A):P451.
188. Petersen HJ, Nielsen CK, Arrigoni-Martelli E. Synthesis and hypotensive activity of N-alkyl-N″-cyano-N′-pyridylguanidines. J Med Chem 1978;21:773-781.
189. Cook NS, Quast U, Manley PW. Potassium channel opening does not alone explain the vasodilator activity of pinacidil and its enantiomers. Br J Pharmacol 1989;96:181P.
190. Anabuki J, Hori M, Ozaka H, Kato I, Karaki H. Mechanisms of pinacidil-induced vasodilation. Eur J Pharmacol 1990;190:373-379.
191. + channel-dependent as well as -independent components of pinacidil-induced vasodilation. J Pharmacol Exp Ther 1991;256:492-499.
192. Xiong Z, Kajioka S, Sakai T, Kitamura K, Kuriyama H. Pinacidil inhibits the ryanodine-sensitive outward current and glibenclamide antagonises its action in cells from the rabbit portal vein. Br J Pharmacol 1991;102:788-790.
193. + treated intact, and in β-escin-treated skinned smooth muscle of the rabbit mesenteric artery. Br J Pharmacol 1991;103:1697-1702.
194. Manley PW, Quast U. Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas. J Med Chem 1992;35:2327-2340.
195. Takemoto T, Eda M, Okada T, Sakashita H, Matzno S, Gohda M, Ebisu H, Nakamura N, Fukaya C, Hihara M, Eiraku M, Yamanouchi K, Yokoyama K. Novel potassium channel openers: Synthesis and pharmacological evaluation of new N-(substituted-3-pyridyl)-N′-alkylthioureas and related compounds. J Med Chem 1994;37:18-25.
196. Eda M, Takemoto T, Ono S, Okada T, Kosaka K, Gohda M, Matzno S, Nakamura N, Fukaya C. Novel potassium channel openers: Preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N′ -bicycloalkyl-N″-cyanoguanidine derivatives. J Med Chem 1994;37:1983-1990.
197. Yoshiizumi K, Ikeda S, Goto K, Morita T, Nishimura N, Sukamoto T, Yoshino K. Synthesis and structure-activity relationships of novel phenylcyanoguanidine derivatives as potassium channel openers. Chem Pharm Bull 1996;44:2042-2050.
198. Yoshiizumi K, Nakajima F, Kiyoi T, Kondo H. NMR analysis of tautomerisms of active pinacidil-type potassium channel openers and a less active one. Bioorg Med Chem Lett 2000;10:2463-2466.
199. ATP channel blockers. J Pharmacol Exp Ther 1997;283:1207-1213.
200. + channels. J Biol Chem 2002;277:40196-40205.
201. Aloup JC, Farge D, James C, Mondot S, Cavero I. 2-(3-Pyridyl)-tetrahydrothiopyran-2-carbothioamide derivatives and analogues: A novel family of potent potassium channel openers. Drugs Fut 1990;15:1097-1108.
202. Mondot S, Mestre M, Caillard CG, Cavero I. RP 49356: A vasorelaxant agent with potassium channel activating properties. Br J Pharmacol 1988;95(Suppl):813P.
203. + channels of cardiac myocytes. Mol Pharmacol 1989;36:897-902.
204. Brown ThJ, Chapman RF, Cook DC, Hart TW, McLay IM, Jordan R, Mason JS, Palfreyman MN, Walsh RJA, Withnall MT, Aloup JC, Cavero I, Farge D, James C, Mondot S. Synthesis and biological activity of trans-(±) N-methyl-2-(3-pyridyl)-2-tetrahydrothiopyrancarbothioamide 1-oxide (RP 49356) and analogues: A new class of potassium channel opener. J Med Chem 1992;35:3613-3624.
205. Palfreyman MN. Syntheses and structure-activity relationships of pyridine based potassium channel activators. In: Evans JM, Hamilton TC, Longman SD, Stemp G, editors. Potassium channels and their modulators. London: Taylor & Francis; 1996. pp 57-77.
206. Brown ThJ, Chapman RF, Mason JS, Palfreyman MN, Vicker N, Walsh RJA. Syntheses and biological activities of potent potassium channel openers derived from (±)-2-oxo-1-pyridin-3-yl-cyclohexanecarbothioic acid methylamide: New potassium channel openers. J Med Chem 1993;36:1604-1612.
207. Seino A, Bessho H, Ishibashi A, Nagano T, Shinpuku T, Tsutsui M, Okushima H, Narimatsu A. Characterization of vasorelaxant action of MCC-134, a novel benzenepropanethioamide derivative. Jpn J Pharmacol 1996;71(Suppl):141P.
208. Umeda A, Bessho H, Abe Y, Ohishi H, Kitada Y. Antihypertensive and cardiohemodynamic effects of a novel vasodilator MCC-134 in rats and dogs. Jpn J Pharmacol 1997;73(Suppl):133P.
209. + channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide. J Pharmacol Exp Ther 1989;250:261-271.
210. Lebrun P, Devreux V, Hermann M, Herchuelz A. Similarities between the effects of pinacidil and diazoxide on ionic and secretory events in rat pancreatic islets. J Pharmacol Exp Ther 1989;250:1011-1018.
211. Antoine M-H, Berkenboom G, Fang Z-Y, Fontaine J, Herchuelz A, Lebrun P. Mechanical and ionic response of rat aorta to diazoxide. Eur J Pharmacol 1992;216:299-306.
212. Pirotte B, deTullio P, Lebrun P, Antoine M-H, Fontaine J, Masereel B, Schynts M, Dupont L, Herchuelz A, Delarge J. 3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine-1,1-dioxides as powerful inhibitors of insulin release from rat pancreatic β-cells: A new class of potassium channel openers? J Med Chem 1993;36:3211-3213.
213. deTullio P, Pirotte B, Lebrun P, Fontaine J, Dupont L, Antoine M-H, Ouedraogo R, Khelili S, Maggetto C, Masereel B, Diouf O, Podona T, Delarge J. 3- and 4-Substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: Synthesis, pharmacological evaluation, and structure-activity relationships. J Med Chem 1996;39:937-948.
214. Khelili S, deTullio P, Lebrun P, Fillet M, Antoine M-H, Ouedraogo R, Dupont L, Fontaine J, Felekidis A, Leclerc G, Delarge J, Pirotte B. Preparation and pharmacological evaluation of the R- and S-enantiomers of 3-(2′-butylamino)-4H- and 3-(3′-methyl-2′ -butylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxide, two tissue selective ATP-sensitive potassium channel openers. Bioorg Med Chem 1999;7:1513-1520.
215. Pirotte B, Ouedraogo R, deTullio P, Khelili S, Somers F, Boverie S, Dupont L, Fontaine J, Damas J, Lebrun P. 3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: Design, synthesis, and pharmacological evaluation. J Med Chem 2000;43:1456-1466.
216. Nielsen FE, Bodvarsdottir TB, Worsaae A, MacKay P, Stidsen CE, Boonen HCM, Pridal L, Arkhammar POG, Wahl P, Ynddal L, Junager F, Dragsted N, Tagmose TM, Mogensen JP, Koch A, Treppendahl SP, Bondo Hansen J. 6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic β-cells. J Med Chem 2002;45:4171-4187.
217. Khelili S, Leclerc G, Faury G, Verdetti J. Synthesis and vasodilator effects of 3- and 7-sulfonylurea-1,2, 4-benzothiadiazin-1,1-dioxides on rat aorta. Bioorg Med Chem 1995;3:495-503.
218. Furukawa K, Itoh T, Kajiwara M, Kitamura K, Suzuki H, Ito Y, Kuriyama H. Vasodilating actions of 2-nicotinamidoethyl nitrate on porcine and guinea-pig coronary arteries. J Pharmacol Exp Ther 1981;218:248-259.
219. Holzmann S. Cyclic GMP as a possible mediator of coronary arterial relaxation by nicorandil (SG-75). J Cardiovasc Pharmacol 1983;5:364-370.
220. Maruyama M, Satoh K, Taira N. Effects of nicorandil and its congeners on musculature and vasculature of the dog trachea in situ. Arch Int Pharmacodyn Ther 1982;258:260-266.
221. Miura K, Koyama H, Sugai T, Yamada H, Sakurai E, Horigome M. 1990; European Patent 385350.
222. Ito Y, Kato H, Etsuchu E, Ogawa N, Mitani K, Iwasaki N, Seiyaku H. 1991; Japanese Patent 89056667-A.
223. Satake N, Kiyoto S, Zhou Q, Matsuo M, Shibata S. Mode of relaxing action of FK336, a new antianginal agent, in rabbit aorta. FASEB J 1992;6:360 (Abstract).
224. Ishibashi T, Hamaguchi M, Imai S. Vasodilating properties of KRN2391: Structural basis of a new pyridine-type potassium channel opener with a nitrate moiety. Naunyn-Schmiedeberg's Arch Pharmacol 1992;346:94-101.
225. Okada Y, Yokoyama T, Jinno Y, Kashiwabara T, Izawa T, Fukushima H, Ogawa N. Vasorelaxant action of Ki1769, a new pyridinecarboximidamide, in isolated porcine coronary artery. Eur J Pharmacol 1993;241:177-181.
226. Longman SD, Hamilton TC. Potassium channel activator drugs: Mechanism of action, pharmacological properties, and therapeutic potential. Med Res Rev 1992;12:73-148.
227. Poyser RH, Hamilton TC. Potassium channel modulators: Current situation and future expectations. Drugs Fut 1994;19:39-47.
228. Lawson K. Is there a therapeutic future for "potassium channel openers"? Clin Sci 1996;91:651-663.
229. Colatsky TJ, Hamilton TC. Potassium channel modulators: clinical experiences and future prospects. In: Evans JM, Hamilton TC, Longman SD, Stemp G, editors. Potassium channels and their modulators. London: Taylor & Francis; 1996. pp 383-411.
230. Lawson K. Potassium channel openers as potential therapeutic weapons in ion channel disease. Kidney Int 2000;57:838-845.
231. Lawson K. Is there a role for potassium channel openers in neuronal ion channel disorders? Expert Opin Investig Drugs 2000;9:2269-2280.
232. Jahangir A, Terzic A, Shen WK. Potassium channel openers: Therapeutic potential in cardiology and medicine. Expert Opin Pharmacother 2001;2:1995-2010.
233. Lawson K, Dunne MJ. Peripheral channelopathies as targets for potassium channel openers. Expert Opin Investig Drugs 2001;10:1345-1359.
234. Atwal KS. Myocardial protection with the ATP-sensitive potassium channel openers. Curr Med Chem 1996;3:227-238.
235. ATP channels in ischemic preconditioning and cardioprotection. Cardiovasc Drugs Ther 2000;14:7-16.
236. Rubino A, Yellon DM. Ischaemic preconditioning of the vasculature: An overlooked phenomenon for protecting the heart? TiPS 2000;21:225-230.
237. Gomma AH, Purcell HJ, Fox KM. Potassium channel openers in myocardial ischaemia. Therapeutic potential of nicorandil. Drugs 2001;61:1705-1710.
238. Lamping K, Gross GJ. Improved recovery of myocardial segmental function following a short coronary occlusion in dogs by nicorandil, a potential new antianginal agent, and nifedipine. J Cardiovasc Pharmacol 1985;7:158-166.
239. Grover GJ, McCullough JR, Henry DE, Conder ML, Sleph PG. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide. J Pharmacol Exp Ther 1989;251:98-104.
240. Grover GJ, Dzwonczyk S, Parham C, Sleph PG. The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs. Cardiovasc Drugs Ther 1990;4:465-474.
241. Grover GJ, Newburger J, Sleph PG, Dzwonczyk S, Taylor S, Ahmed S, Atwal KS. Cardioprotective effects of the potassium channel opener cromakalim: Stereoselectivity and effects on myocardial adenine nucleotides. J Pharmacol Exp Ther 1991;257:156-162.
242. Grover GJ, Dzwonczyk S, Sleph PG. Reduction of ischemic damage in isolated rat hearts by the potassium channel opener RP 52891. Eur J Pharmacol 1990;191:11-19.
243. Ohta H, Jinno Y, Harada K, Ogawa N, Fukushima H, Nishikori K. Cardioprotective effects of KRN2391 and nicorandil on ischemic dysfunction in perfused rat heart. Eur J Pharmacol 1991;204:171-177.
244. Galinanes M, Shattock M, Hearse D. Effects of potassium channel modulation during global ischemia in isolated rat heart and without cardioplegia. Cardiovasc Res 1992;26:1063-1068.
245. Tan H, Mazón P, Verberne H, Sleeswijk M, Coronel R, Opthof T, Janse M. Ischaemic preconditioning delays the ischaemia induced cellular electrical uncoupling in rabbit myocardium by activation of ATP sensitive potassium channels. Cardiovasc Res 1993;27:644-651.
246. Armstrong S, Liu G, Downey J, Ganote C. Potassium channels and preconditioning of isolated rabbit cardiomyocytes: Effects of glyburide and pinacidil. J Mol Cell Cardiol 1995;27:1765-1774.
247. Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 1990;66:913-931.
248. Liu GS, Thornton J, van Winkle DM, Stanley AW, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1-adenosine receptors in rabbit heart. Circulation 1991;84:350-356.
249. Goto M, Liu Y, Yang X-M, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995;77:611-621.
250. Tanaka M, Fujiwara H, Yamasaki K, Sasayama S. Superoxide dismutase and N-2-mercaptopropionyl glycine attenuate infarct size limitation effect of ischaemic preconditioning in the rabbit. Cardiovasc Res 1994;28:980-986.
251. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by proteine kinase C activation. Amer J Physiol 1994;266:H1145-H1152.
252. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992;70:223-233.
253. Auchampach JA, Grover GJ, Gross GJ. Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate. Cardiovasc Res 1992;26:1054-1062.
254. McCullough JR, Normandin DE, Conder ML, Sleph PG, Dzwonczyk S, Grover GJ. Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate. Circ Res 1991;69:949-958.
255. ATP-channel blockers on ischemic preconditioning. J Mol Cell Cardiol 1998;30:A18.
256. ATP in the heart - What happens, and what does not happen. Basic Res Cardiol 2000;95:275-279.
257. ATP channels in cardioprotection. Basic Res Cardiol 2000;95:280-284.
258. ATP channels in cardioprotection. Basic Res Cardiol 2000;95:285-289.
259. ATP channels in ischemic cardioprotection. Circulation 2000;101:2418-2423.
260. ATP channel as a receptor for potassium channel openers. J Biol Chem 1996;271:8796-8799.
261. Liu Y, Sato T, O'Rourke B, Marbán E. Mitochondrial ATP dependent potassium channels: Novel effectors of cardioprotection? Circulation 1998;97:2463-2469.
262. Garlid KD, Paucek P, Yarov-Yarovoy B, Murray HNM, Darbenzio RB, D'Alonzo AJ, Lodge NJ, Smith MA, Grover GJ. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP sensitive potassium channels. Possible mechanism of cardioprotection. Circ Res 1997;81:1072-1082.
263. + channels by protein kinase C. Circ Res 1998;83:110-114.
264. + channels modulate cardiac mitochondrial function. Am J Physiol 1998;275:H1567-H1576.
265. ATP channels and actin cytoskeleton. Am J Physiol 1999;276: H1361-H1368.
266. + channel for cardiac protection against ischemic injury is dependent on protein kinase C activity. Circ Res 1999;85:731-741.
267. 2+ overload in rat cardiac mitochondria. J Physiol 1999;519:347-360.
268. ATP channel opening protects a human atrial-derived cell line by a mechanism involving free radical generation. Cardiovasc Res 2001;51:691-700.
269. ATP channel openers activate the ERK kinase by an oxidant-dependent mechanism. Am J Physiol 2002;283: C273-C281.
270. ATP channels. Naunyn Schmiedeberg's Arch Pharmacol 2001;364:226-232.
271. ATP channels in adenosine-enhanced ischemic preconditioning. Am J Physiol 2000;279: H2694-H2703.
272. ATP channels, and protein kinase C. J Am Coll Cardiol 2002;40:1523-1530.
273. ATP channels in cardioprotection against ischemia/reperfusion in mice. J Clin Invest 2002;109:509-516.
274. Grover GJ, Sleph PG, Dzwonczyk S. Pharmacologic profile of cromakalim in the treatment of myocardial ischemia in isolated rat hearts and anesthetized dogs. J Cardiovasc Pharmacol 1990;16:853-864.
275. + channel opener, and cromakalim in rat and dog. Eur J Pharmacol 1995;294:271-280.
276. Atwal KS, Grover GJ, Ahmed SZ, Ferrara FN, Harper TW, Kim KS, Sleph PG, Dzwonczyk S, Russell AD, Moreland S, McCullough JR, Normandin DE. Cardioselective anti-ischemic ATP-sensitive potassium channel openers. J Med Chem 1993;36:3971-3974.
277. Grover GJ, McCullough JR, D'Alonzo AJ, Sargent CA, Atwal KS. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448. J Cardiovasc Pharmacol 1995;25:40-50.
278. ATP openers. J Cardiovasc Pharmacol 1994;24:S12-S17.
279. Atwal KS, Grover GJ, Ferrara FN, Ahmed SZ, Sleph PG, Dzwonczyk S, Normandin DE. Cardioselective antiischemic ATP-sensitive potassium channel openers. 2. Structure-activity studies on benzopyranyl-cyanoguanidines: Modification of the benzopyran ring. J Med Chem 1995;38:1966-1973.
280. Atwal KS, Grover GJ, Ahmed SZ, Sleph PG, Dzwonczyk S, Baird AJ, Normandin DE. Cardioselective antiischemic ATP-sensitive potassium channel openers. 3. Structure-activity studies on benzopyranyl cyanoguanidines: Modification of the cyanoguanidine portion. J Med Chem 1995;38:3236-3245.
281. Atwal KS, Ferrara FN, Ding CZ, Grover GJ, Sleph PG, Dzwonczyk S, Baird AJ, Normandin DE. Cardioselective antiischemic ATP-sensitive potassium channel openers. 4. Structure-activity studies on benzopyranyl cyanoguanidines: Replacement of the benzopyran portion. J Med Chem 1996;39:304-313.
282. ATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity. J Med Chem 1997;40:24-34.
283. ATP) openers. 6. Effect of modifications at C6 of benzopyranyl cyanoguanidines. J Med Chem 1999;42:3711-3717.
284. ATP opener with no peripheral vasodilator or cardiac action potential shortening activity. J Pharmacol Exp Ther 2001;297:1184-1192.
285. ATP opener BMS-191095 for treatment of acute myocardial ischemia. Cardivasc Drug Rev 2002;20:121-136.
286. ATP opener (3R)-trans-4-((4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl) dimethyl-2H-1-benzopyran-6-carbonitril monohydrochloride (BMS-191095): Cardioprotective, hemodynamic, and electrophysiological effects. J Pharmacol Exp Ther 2002;303:132-140.
287. Raeburn D, Karlsson J-A. Potassium channel openers: Airway pharmacology and clinical possibilities in asthma. Progr Drug Res 1991;37:161-180.
288. + channel openers and suppression of airway hyperreactivity. TiPS 1994;15:463-468.
289. Arch JRS. Potassium channel activators: Airway pharmacology and bronchial asthma. In: Evans JM, Hamilton TC, Longman SD, Stemp G, editors. Potassium channels and their modulators. London: Taylor & Francis; 1996. pp 275-302.
290. ATP channel openers for the treatment of airways hyperreactivity. Pulm Pharmacol Ther 1999;12:103-105.
291. Prasad MR, Bahekar RH, Rao AR. Recent perspectives in the design of antiasthmatic agents. Pharmazie 2000;55:475-482.
292. Pelaia G, Gallelli L, Vatrella A, Grembiale RD, Maselli R, De Sarro GB, Marsico SA. Potential role of potassium channel openers in the treatment of asthma and chronic obstructive pulmonary disease. Life Sci 2002;70:977-990.
293. Allen SL, Boyle JP, Cortijo J, Foster RW, Morgan GP, Small RC. Electrical and mechanical effects of BRL34915 in guinea-pig isolated trachealis. Br J Pharmacol 1986;89:395-405.
294. Longmore J, Bray KM, Weston AH. The contribution of Rb-permeable potassium channels to the relaxant and membrane hyperpolarizing actions of cromakalim, RP49356 and diazoxide in bovine tracheal smooth muscle. Br J Pharmacol 1991;102:979-985.
295. Buckle DR, Arch JRS, Bowring NE, Foster KA, Taylor JF, Taylor SG, Shaw DJ. Relaxant effects of the potassium channel activators BRL 38227 and pinacidil on guinea-pig and human airway smooth muscle, and blockade of their effects by glibenclamide and BRL 31660. Pulm Pharmacol 1993;6:77-86.
296. Bowring NE, Arch JRS, Buckle DR, Taylor JF. Comparison of the airways relaxant and hypotensive potencies of the potassium channel activators BRL 55834 and levcromakalim (BRL 38227) in vivo in guinea-pigs and rats. Br J Pharmacol 1993;109:1133-1139.
297. Arch JRS, Buckle DR, Bumstead J, Clarke GD, Taylor JF, Taylor SG. Evaluation of the potassium channel activator cromakalim (BRL 34915) as a bronchodilator in the guinea pig: Comparison with nifedipine. Br J Pharmacol 1988;95:763-770.
298. Englert HC, Wirth K, Gehring D, Fürst U, Albus U, Scholz W, Rosenkranz B, Schölkens BA. Airway pharmacology of the potassium channel opener, HOE 234, in guinea pigs: In vitro and in vivo studies. Eur J Pharmacol 1992;210:69-75.
299. Chapman ID, Kristersson A, Mathelin G, Schaeublin E, Mazzoni L, Boubekeur K, Murphy N, Morley J. Effects of a potassium channel opener (SDZ PCO 400) on guinea-pig and human pulmonary airways. Br J Pharmacol 1992;106:423-429.
300. Taylor SG, Arch JRS, Bond J, Buckle DR, Shaw DJ, Taylor JF, Ward JS. The inhibitory effects of cromakalim and its active enantiomer BRL 38227 against various agonists in guinea-pig and human airways: Comparison with pinacidil and verapamil. J Pharmacol Exp Ther 1992;261:429-437.
301. Underwood SL, Raeburn D. Adenosine triphosphate-activated potassium channels. In: Raeburn D, Giembycz MA, editors. Airways smooth muscle development and regulation of contractility. Basel: Birkhäuser Verlag; 1994. pp 199-216.
302. Buckle DR, Arch JRS. Potassium channel activators and airways disease. Drugs News Persp 1993;6:279-288.
303. Yamamoto A, Shikada K, Tanaka S. Effects of anti-asthma drugs and potassium channel openers on neurally-mediated contraction of isolated guinea pig trachea. Jap J Pharmacol 1992;59:129-132.
304. Clapham JC, Bowring NE, Trail BK, Fuller DA, Good DM. Effects of levcromakalim and RP52891 on NANCe nerve-mediated changes in pulmonary dynamics evoked by vagal stimulation in the guinea-pig. Pulm Pharmacol 1993;6:201-208.
305. Small RC, Berry JL, Cook SJ, Foster RW, Green KA, Murray MA. Potassium channels in airways. In: Chung KF, Barnes PJ, editors. Pharmacology of the respiratory tract: Experimental and clinical research. New York, NY: Marcel Dekker; 1993. pp 137-176.
306. Kuo H-P, Rhode JAL, Tokuyama K, Barnes PJ, Rogers DF. Capsaicin and sensory neuropeptide stimulation of goblet cell secretion in guinea-pig trachea. J Physiol 1990;431:629-641.
307. + channel activator inhibition of neurogenic goblet cell secretion in guinea pig trachea. Eur J Pharmacol 1992;215:297-299.
308. Martin CAE, Advenier C. Effects of cromakalim on bradykinin-, histamine- and substance P-induced airway microvascular leakage in the guinea-pig. Eur J Pharmacol 1993;239:119-126.
309. + channel activator, BRL 38227, in guinea pig airways in vivo. Eur J Pharmacol 1993;239:257-259.
310. Gallico L, Ferrario A, Piazzoni L, Ceserani R. Effects of anti-asthma drugs on microvascular leakage induced by platelet activating factor in rat airways. Br J Pharmacol 1994;111:237P.
311. Ward JS, Spicer BA, Taylor SG. Effects of lemakalim (BRL 38227) and salbutamol on hyperresponsive lung parenchyma. Br J Pharmacol 1990;100:369P.
312. + channel activation in tests for prophylactic anti-asthma drug efficacy in the guinea-pig. Am Rev Respir Dis 1989;139:A467.
313. Paciorek PM, Spence AM, Gater PR, Waterfall JF. PAF-induced hyperreactivity in the guinea-pig is inhibited by RO 31 6930 and salmeterol. In: Vargaftig BB, Tarayre JP, Carilla E, editors. New concepts in asthma. London: MacMillan Press; 1993. 299 p.
314. Ishizawa T, Koga H, Sato H, Makino T, Taka N, Takahashi T, Sato T, Nabata H. Substituent effects of benzopyran-4-(N-cyano)-carboxamidine potassium channel openers for selectivity to guinea pig trachealis. Bioorg Med Chem Lett 1994;4:1995-1998.
315. Koga H, Sato H, Ishizawa T, Kuromaru K, Nabata H, Imagawa J, Yoshida S, Sugo I. N,N-disubstituted benzopyran-4-(N′-cyano)-carboxamidines, cromakalim analogs with selective activity for guinea pig trachealis. Bioorg Med Chem Lett 1993;3:1111-1114.
316. Taylor SG, Buckle DR, Shaw DJ, Ward JS, Arch JRS. An investigation of the selectivities of BRL 55834 and BRL 38227 as relaxants of guinea-pig tracheal spirals relative to portal vein. Br J Pharmacol 1992;105:242P.
317. Fozard JR, Büscher H. Comparison of the anti-bronchoconstrictor activities of inhaled formoterol, its (R,R)- and (S,S)-enantiomers and salmeterol in the rhesus monkey. Pulm Pharmacol Ther 2001;14:289-295.
318. Hattori T. Drug treatment of urinary incontinence. Drugs of Today 1998;34:125-138.
319. Brading AF, Turner WH. Potassium channels and their modulation in urogenital smooth muscles. In: Evans JM, Hamilton TC, Longman SD, Stemp G, editors. Potassium channels and their modulators. London: Taylor & Francis; 1996. pp 335-359.
320. Andersson K-E. Advances in the pharmacological control of the bladder. Exp Physiol 1999;84:195-213.
321. Sellers DJ, Chapple CR, Chess-Williams R. Potential therapeutic targets for treatment of the overactive bladder. World J Urol 2001;19:307-311.
322. Wein AJ. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opin Investig Drugs 2001;10:65-83.
323. 2+ concentration jumps in excised inside-out multi-channel patches (myocytes from guinea pig urinary bladder). J Gen Physiol 1992;99:841-862.
324. ATP) expressed in guinea pig bladder smooth muscle cells. J Pharmacol Exp Ther 1999;289:551-558.
325. + channel modulators on detrusor and portal vein strips from guinea pigs. Pharmacology 1992;45:216-230.
326. Martin SW, Radley SC, Chess-Williams R, Korstanje C, Chapple CR. Relaxant effects of potassium channel openers on normal and hyper-reflexic detrusor muscle. Br J Urol 1997;80:405-413.
327. Chess-Williams R, Martin SW, Korstanje C, Chapple CR. In vitro investigation of the bladder-vascular selectivity of levcromakalim and YM934 in human tissues. Br J Urol Int 1999;83:1050-1054.
328. Wojdan A, Freeden C, Woods M, Oshiro G, Spinelli W, Colatsky TJ, Sheldon JH, Norton NW, Warga D, Antane MM, Antane SA, Butera JA, Argentieri TM. Comparison of the potassium channel openers, WAY-133537, ZD6169, and celikalim on isolated bladder tissue and in vivo bladder instability. J Pharmacol Exp Ther 1999;289:1410-1418.
329. Malmgren A, Andersson KE, Sjogren C, Andersson PO. Effects of pinacidil and cromakalim (BRL 34915) on bladder function in rats with detrusor instability. J Urol 1989;142:1134-1138.
330. ATP channel opener, on bladder hyperactivity and spinal c-fos expression evoked by bladder irritation in rats. Brain Res 1998;807:11-18.
331. ATP channel opener, on the micturition reflex in the rat. J Pharmacol Exp Ther 1999;290:825-831.
332. Foster CD, Speakman MJ, Fujii K, Brading AF. The effects of cromakalim on the detrusor muscle of human and pig urinary bladder. Brit J Urol 1989;63:284-294.
333. Nurse DE, Restorick JM, Mundy AR. The effect of cromakalim on the normal and hyper-reflexic detrusor muscle. Brit J Urol 1991;68:27-31.
334. Cheng C-Y, Chiu H-I, Chang M-J, Lin Y-C, Tsai M-C, Yu H-C. Synthesis of 2,3,4a,11b-tetrahydro-oxazino[2,3-c]benzopyran-9-carbonitriles as ATP-sensitive potassium channel openers. Bioorg Med Chem Lett 1998;8:463-468.
335. Chiu H-I, Lin Y-C, Cheng C-Y, Tsai M-C, Yu H-C. N-Acyl-1,2,3,4a,5,10b-hexahydro-[1]benzopyrano-[3,4b][1,4] oxacine-9-carbonitriles as bladder-selective potassium channel openers. Bioorg Med Chem 2001;9:383-393.
336. Butera JA, Antane MM, Antane SA, Argentieri TM, Freeden C, Graceffa RF, Hirth BH, Jenkins D, Lennox JR, Matelan E, Norton NW, Quagliato D, Sheldon JH, Spinelli W, Warga D, Wojdan A, Woods M. Design and SAR of novel potassium channel openers targeted for urge urinary incontinence I. N-cyanoguanidine bioisosteres possessing in vivo bladder selectivity. J Med Chem 2000;43:1187-1202.
337. Gilbert AM, Antane MM, Argentieri TM, Butera JA, Francisco GD, Freeden C, Gundersen EG, Graceffa RF, Herbst D, Hirth BH, Lennox JR, McFarlane G, Norton NW, Quagliato D, Sheldon JH, Warga D, Wojdan A, Woods M. Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 2. Selective and potent benzylamino cyclobutenediones. J Med Chem 2000;43:1203-1214.
338. Butera JA, Argentieri TM. KCO-616. Drugs Fut 2000;25:239-245.
339. Höltje H-D, Marrer S. A molecular graphics study on structure-action relationships of calcium-antagonistic and agonistic 1,4-dihydropyridines. J Comp-Aid Mol Design 1987;1:23-30.
340. Kaji DM. Nifedipine inhibits calcium-activated K transport in human erythrocytes. Am J Physiol Cell Physiol 1990;259:C332-C339.
341. Klöckner U, Trieschmann U, Isenberg G. Pharmacological modulation of calcium and potassium channels in isolated vascular smooth muscle cells. Arzneim-Forsch/Drug Res 1989;39:120-126.
342. 3H-P1075 binding in urinary bladder smooth muscle. Res Commun Mol Pathol Pharmacol 1995;88:137-151.
343. ATP channel opening activity of the new dihydropyridine compound 9-(3-cyanophenyl)-3,4,6,7,9,10-hexahydro-1,8-(2H,5H)-acridinedione in bladder detrusor in vitro. Arzneim-Forsch/Drug Res 1996;46:525-530.
344. ATP channel activator. Cardiovasc Drug Rev 1997;15:220-231.
345. Steers WD. The future of direction of neuro-urology drug research. Curr Opin Centr Peripher Nerv Syst Invest Drugs 2000;2:268-282.
346. Gopalakrishnan M, Buckner SA, Whiteaker KL, Shieh C-C, Molinari EJ, Milicic I, Daza AV, Davis-Taber R, Scott VE, Sellers D, Chess-Williams R, Chapple CR, Liu Y, Liu D, Brioni JD, Sullivan JP, Williams M, Carroll WA, Coghlan MJ. (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b] quinolin-8(4H)-one 1,1-dioxide (A-278637): A novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization. J Pharmacol Exp Ther 2002;303:379-386.
347. Brune ME, Fey TA, Brioni JD, Sullivan JP, Williams M, Carroll WA, Coghlan MJ, Gopalakrishnan M. (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b] quinolin-8(4H)-one 1,1-dioxide (A-278637): A novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. II. In vivo characterization. J Pharmacol Exp Ther 2002;303:387-394.
348. ATP channel openers (KCOs). Bioorg Med Chem Lett 2002;12:1481-1484.
349. Morris JJ, Hughes LR, Glen AT, Taylor PJ. Non-steroidal antiandrogens. Design of novel compounds based on infrared study of the dominant conformation and hydrogen-bonding properties of a series of anilide antiandrogens. J Med Chem 1991;34:447-455.
350. + channel openers. Trends Pharmacol Sci 1994;15:402-404.
351. 3H-P1075 binding in bladder smooth muscle. Pharmacol 1995;50:388-397.
352. Grant TL, Frank CA, Kau ST, Li JH, McLaren FM, Ohnmacht CJ, Russell K, Shapiro HS, Trivedi S. Anilide tertiary carbinols: A new structural class of potent potassium channel openers. Bioorg Med Chem Lett 1993;3:2723-2724.
353. ATP potassium channel openers. Modifications on the western region. J Med Chem 1996;39:4592-4601.
354. 2-stimulated bladder activity in conscious rats. J Urol 1997;158:2300-2304.
355. ATP channel opener with in vivo selectivity for urinary bladder. J Pharmacol Exp Ther 1995;274:884-890.
356. Yoshida M, Seishi T, Aono S, Takai H, Suzuki K, Yamagata T, Atsuki K, Karasawa A, Kumazawa T. 1998. New tricyclic compounds. EP979821 A1 Patent
357. Yoshida M, Sasaki S, Aono S, Fujiwara S, Takai H, Yamagata T, Nagashima K, Karasawa A. 1998. Tricyclic compounds. U.S. Patent 5,726,325
358. Liang P-H, Hsin L-W, Cheng C-Y. N-arylated pyrrolidin-2-ones and morpholin-3-ones as potassium channel openers. Bioorg Med Chem 2002;10:3267-3276.
359. ATP channel opener. XVIIth Int Symp Med Chem, Barcelona; Drugs Fut 27(Suppl A):C47.